Print

C86P1

A Phase I, Open Label, Parallel Group Trial To Evaluate Safety And Immunogenicity Of Three Nasal Immunisations Using A Fixed Dose-Level Of HIV gp140 V2 Loop Deleted Protein Adjuvanted With LTK63 Followed By Intramuscular Boosting With HIV gp140 V2 Loop Deleted Protein Adjuvanted With MF59 When Administered To Healthy Adults

Trial Details:

I Completed
St. George's University of London, Richmond Pharmacology Ltd, Novartis, European Union Commission September 01, 2006
HIV gp140 ZM96 Env gp140 C ZM96
HIV gp140 ZM96 Protein
MF59
United Kingdom 30
NCT00369031
http://clinicaltrials.gov/ct/show/NCT00369031